Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-21-005683
Filing Date
2021-11-15
Accepted
2021-11-15 15:45:38
Documents
45
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q coeptis_i10q-093021.htm   iXBRL 10-Q 638708
2 CERTIFICATION coeptis_ex3101.htm EX-31.1 7633
3 CERTIFICATION coeptis_ex3102.htm EX-31.2 7639
4 CERTIFICATION coeptis_ex3201.htm EX-32.1 2391
5 CERTIFICATION coeptis_ex3202.htm EX-32.2 2396
  Complete submission text file 0001683168-21-005683.txt   2742279

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE coep-20210930.xsd EX-101.SCH 22815
7 XBRL CALCULATION FILE coep-20210930_cal.xml EX-101.CAL 45089
8 XBRL DEFINITION FILE coep-20210930_def.xml EX-101.DEF 72805
9 XBRL LABEL FILE coep-20210930_lab.xml EX-101.LAB 195108
10 XBRL PRESENTATION FILE coep-20210930_pre.xml EX-101.PRE 149450
11 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_i10q-093021_htm.xml XML 259634
Mailing Address 105 BRADFORD RD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD RD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Inc. (Filer) CIK: 0001819663 (see all company filings)

EIN.: 843998117 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-56194 | Film No.: 211409824
SIC: 2834 Pharmaceutical Preparations